Since both Th2 and Treg cells express high levels of CD194 (30, 61), a therapeutic target in SS/MF patients (62), such treatments could further deplete these subpopulations (63), and therefore, potentially exacerbate the pre-established immunodeficiency status in these patients. This evidence concerns the gene CCR4 and synovial sarcoma.